Latest Period
n/a
Security Snapshot
INOTEK PHARMACEUTICALS CORP - COM (ITEK) Institutional Ownership
CUSIP: 45780V102
13F Institutional Holders and Ownership History from Q1 2015 to Q4 2021
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COM
- Symbol
- ITEK
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ITEK - INOTEK PHARMACEUTICALS CORP - COM is tracked under CUSIP 45780V102.
- Latest finished 13F holder period is not available.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 1 to 0 between Q3 2021 and Q4 2021.
- SEC-reported value moved from $224,000 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
45780V102
Latest holder period
n/a
13F holders
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45780V102:
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
n/a
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2021 Q4 | 0 | $0 | -$224,000 | 0 | |
| 2021 Q3 | 7,500 | $224,000 | +$224,000 | $29.87 | 1 |
| 2018 Q1 | 0 | $0 | -$31,016,000 | 0 | |
| 2017 Q4 | 11,886,255 | $31,021,000 | +$9,271,280 | $2.61 | 31 |
| 2017 Q3 | 8,924,973 | $15,885,007 | +$6,647,026 | $1.78 | 30 |
| 2017 Q2 | 7,874,608 | $14,955,008 | -$4,014,656 | $1.90 | 47 |
| 2017 Q1 | 10,346,681 | $20,690,204 | -$46,989,216 | $2.00 | 64 |
| 2016 Q4 | 17,806,802 | $108,615,996 | -$10,162,154 | $6.10 | 81 |
| 2016 Q3 | 21,794,703 | $206,607,778 | +$19,450,707 | $9.48 | 78 |
| 2016 Q2 | 19,722,484 | $146,730,848 | +$4,604,833 | $7.44 | 65 |
| 2016 Q1 | 19,130,683 | $141,563,460 | -$10,368,061 | $7.40 | 58 |
| 2015 Q4 | 19,217,106 | $217,725,768 | +$6,681,357 | $11.33 | 60 |
| 2015 Q3 | 18,620,602 | $175,057,000 | +$83,705,455 | $9.40 | 53 |
| 2015 Q2 | 10,417,182 | $51,045,000 | +$3,482,631 | $4.90 | 18 |
| 2015 Q1 | 9,687,952 | $52,499,000 | +$52,499,000 | $5.42 | 15 |